PET scans track treatment response in people with light chain cardiac amyloidosis
Uses PET scans to check for changes in adults treated for heart amyloidosis.
Plain-language title generated from the registry record
Registry title: Beta-amyloid PET/CT to Measure Potential Therapeutic Response in AL-CA
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
Where in China
- Peking Union Medical College HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT07829705
- Record updated
- 21 September 2026
- Original description
This was a single center, prospective cohort study that is evaluating the ability of beta-amyloid dynamic PET/CT to detect potential therapeutic changes in subjects under treatment for AL-CA after one year had elapsed since their baseline beta-amyloid PET/CT. Demographic, clinical and PET imaging data were collected to characterize potential changes since their baseline scans.Read full original descriptionShow less
A Follow-Up Study to Monitor Therapeutic Response in Light Chain Cardiac Amyloidosis Using Beta-amyloid PET/CT
This was a single center, prospective cohort study that is evaluating the ability of beta-amyloid dynamic PET/CT to detect potential therapeutic changes in subjects under treatment for AL-CA after one year had elapsed since their baseline beta-amyloid PET/CT. Demographic, clinical and PET imaging data were collected to characterize potential changes since their baseline scans.
Inclusion: Age ≥ 18 y；; were proven newly diagnosed AL-CA by standard criteria; subsequently received first-line therapies including anti-plasma cell therapy or targeted therapy; must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.
Exclusion: received therapy with an approved treatment (e.g., Bortezomib, Daratumumab) prior to enrollment; any condition deemed by the investigator to interfere with study results or increase participant risk; pregnancy or breastfeeding; severe claustrophobia.